A Novel Selective ERK1/2 Inhibitor, Laxiflorin B, Targets EGFR Mutation Subtypes in Non-Small-Cell Lung Cancer

Scientists identified a potential novel covalent extracellular regulated protein kinase (ERK) inhibitor, Laxiflorin B, which is a herbal compound with anticancer activity.